Trulicity (dulaglutide) / Eli Lilly - LARVOL DELTA

Short- and long-acting GLP-1 receptor agonists decrease female sexual behaviors in experienced rodents. (PubMed, Behav Brain Res) - "While the short-acting GLP-1R agonist exendin-4 (Ex-4) reduces sexual behaviors in sexually naïve male mice, the effects of long- versus short-acting GLP-1R agonists on natural rewards, such as sexual and social behaviors, in females remain unexplored. In the current study, we investigate the effects of both long-acting (dulaglutide, liraglutide) and short-acting (Ex-4) GLP-1R agonists on sexual and social behaviors in sexually experienced female rats and mice...Moreover, the long-acting GLP-1R agonists increased sociability and the time to seek a novel object. These results highlight species-dependent and agonist-specific effects of GLP-1R activation on sexual and social function in females and expands our understanding of the broader role of GLP-1."

Journal • Preclinical • CNS Disorders • Psychiatry • NTS

Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis. (PubMed, Cancers (Basel)) - "In the first analysis, adult patients with pre-existing CP were identified and stratified by use of a GLP-1 RA (semaglutide, dulaglutide, tirzepatide, exenatide, liraglutide, lixisenatide, and albiglutide). Propensity score matching (PSM) was conducted between GLP1-RA users and non-users, matching for age, sex, race, tobacco use, alcohol use, hypertension, hyperlipidemia, obesity, and pancreatic cysts...Given the elevated cancer risk in CP, these findings suggest a potential beneficial effect of GLP-1RA use in this high-risk population. Prospective studies will be important to further analyze and confirm this potential benefit."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Hypertension • Metabolic Disorders • Obesity • Oncology • Pancreatic Cancer • Pancreatitis • Solid Tumor • Type 2 Diabetes Mellitus

Dulaglutide and pregnancy: a comprehensive safety assessment using the ex vivo placenta perfusion and in vitro models. (PubMed, Front Pharmacol) - "Our results suggest that dulaglutide has no adverse effects on placental viability and functions and is not able to cross the placental barrier at earlier gestation stages. However, its ability to cross the placental barrier at term in minimal amounts, but consistently, indicates foetal exposure during late pregnancy, when FcRn is expressed."

Journal • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • RAB5A

Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes. (PubMed, JAMA Netw Open) - "Initiation of GLP-1 RAs (liraglutide, dulaglutide, or semaglutide) vs DPP-4 inhibitors. In this nationwide cohort study of patients with diabetes and prior MALEs, treatment with GLP-1 RAs was associated with significantly lower risks of recurrent limb events, cardiovascular events, all-cause mortality, and kidney disease progression compared with DPP-4 inhibitors. These findings support the preferential use of GLP-1 RAs for secondary prevention in this high-risk population."

Adverse events • Journal • Retrospective data • Cardiovascular • Diabetes • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Nephrology • Peripheral Arterial Disease • Renal Disease

Negotiations with participating drug companies will occur in 2026 and any negotiated and renegotiated prices will become effective January 1, 2028. (CMS Press Release) - "The selected drug list for the third cycle of negotiations is: Anoro Ellipta...Botox; Botox Cosmetic; Cimzia; Cosentyx; Entyvio...Orencia...Trulicity....Xeljanz; Xeljanz XR; Xolair."

Medicare • Allergy • Ankylosing Spondylitis • Asthma • Chronic Obstructive Pulmonary Disease • Crohn's disease • Idiopathic Arthritis • Immunology • Migraine • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Ulcerative Colitis

DULAGLUTIDE PROMOTES CORONARY PLAQUE STABILIZATION IN PATIENTS WITH TYPE 2 DIABETES: AN OPTICAL COHERENCE TOMOGRAPHY STUDY (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia (clinicaltrials.gov) - P2 | N=80 | Completed | Sponsor: Ain Shams University

New P2 trial • Beta-Thalassemia • Congestive Heart Failure • Diabetes • Genetic Disorders • Metabolic Disorders

Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice. (PubMed, J Diabetes Investig) - "Endogenous GIP signaling is essential for both glucose-lowering and anti-obesity actions of DPP-4 inhibitors in mice. GLP-1 elevation alone is insufficient to compensate for GIP receptor deficiency. These findings refined the mechanistic understanding of DPP-4 inhibitors, highlighted the physiological importance of GIP, and suggested context-dependent metabolic actions of incretins."

Journal • Preclinical • Genetic Disorders • Obesity

Effects Of Tirzepatide Compared With Dulaglutide On Expanded Cardiorenal Outcomes (ACC 2026) - "Abstract is embargoed at this time."

Late-breaking abstract

A cardiovascular indication for oral semaglutide (Rybelsus). (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Calculating cost per event avoided using a composite number needed to treat. (PubMed, J Med Econ) - P3 | "This research aims to overcome this limitation by developing multiple composite NNTs to derive the CPEA to estimate a total value of semaglutide and dulaglutide in people with established cardiovascular disease. This research illustrates the limitations of using a NNT focused only on the primary endpoint, as it does not capture the total benefit of the treatment. When considering the value of treatments through NNT or CPEA analyses, a composite endpoint capturing broader benefit should be utilized."

Journal • Cardiovascular

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) (clinicaltrials.gov) - P3 | N=55 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Jul 2026 ➔ Dec 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2027

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Pediatrics • Type 2 Diabetes Mellitus

Annals On Call - Dulaglutide, Semaglutide, and Tirzepatide: How Do Gastrointestinal Adverse Effects Compare? (PubMed, Ann Intern Med) - No abstract available

Adverse events • Journal

Clinical Presentation of a Child With a Novel ALMS1 Variant Associated With Alström Syndrome and Favorable Response to GLP-1 Receptor Agonist Therapy. (PubMed, Am J Med Genet A) - "Due to accelerated weight gain and declining glycemic control, dulaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was initiated. Over 48 weeks, BMI decreased from 190% to 160% of the 95th percentile, with a 0.95 z-score reduction, 1.2% HbA1c decrease into the normal range. This case expands our understanding of the ALMS1 mutational spectrum and provides the first longitudinal report of GLP-1 RA benefit in AS, supporting its consideration as adjunctive therapy and highlighting the need for further study."

Journal • Alstrom Syndrome • Diabetes • Dyslipidemia • Genetic Disorders • Metabolic Disorders • Otorhinolaryngology

Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery (clinicaltrials.gov) - P=N/A | N=94 | Completed | Sponsor: Ciusss de L'Est de l'Île de Montréal | Not yet recruiting ➔ Completed

Trial completion

GBGT: A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Effects of GLP-1 Receptor Agonists on Copeptin in Euvolemic Participants. (PubMed, Eur J Endocrinol) - "Our analysis provides evidence that the GLP-1-RA dulaglutide inhibits the vasopressin system and proposes physiological mechanisms that may explain the role of GLP-1 in sodium and water balance."

Clinical • Journal

Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management. (PubMed, Int J Mol Sci) - "The latest classes of glucose-lowering drugs introduced in the clinical practice are DPP4 inhibitors (sitagliptin, saxagliptin, vildagliptin, linagliptin, and alogliptin), GLP-1 receptor agonists (semaglutide, liraglutide, albiglutide, dulaglutide, exenatide, and lixenatide), and SGLT-2 inhibitors (empaglifozin, canaglifozin, and dapaglifozin). Multiple lines of evidence show that all these new drugs associated with the treatment of diabetic disease have the same effectiveness as the traditional antidiabetic drugs, and excellent cardiovascular safety, highlighting their potential in significantly reducing major cardiovascular events and mortality. The aim of our review is to summarise the clinical efficacy of these recently introduced drugs to optimise treatment strategies, especially in the early phase of diabetic disease."

Journal • Review • Cardiovascular • Diabetes • Metabolic Disorders

Glucagon-like peptide-1 receptor agonists and risk of osteoarthritis among individuals with type 2 diabetes: A population-based cohort study. (PubMed, Diabetes Res Clin Pract) - "The use of GLP-1RAs, primarily dulaglutide, was not associated with lower risk of osteoarthritis compared with DPP4Is use among patients with T2DM."

Journal • Diabetes • Immunology • Metabolic Disorders • Osteoarthritis • Pain • Rheumatology • Type 2 Diabetes Mellitus

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists (clinicaltrials.gov) - P4 | N=60 | Active, not recruiting | Sponsor: MaryAnn Banerji

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States. (PubMed, Diabetes Obes Metab) - "Among United States Medicare Optum CDM enrolees with T2D and ASCVD, semaglutide was associated with reduced risks of CV outcomes compared with dulaglutide. These results help to address an important evidence gap in selecting glucagon-like peptide-1 receptor agonists for this high-risk population."

Journal • Atherosclerosis • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review. (PubMed, J Sex Med) - "GLP-1RAs may improve testosterone levels and potentially enhance semen quality in men with metabolic issues, while maintaining gonadotropin function. They could serve as fertility-sparing alternatives to testosterone therapy in some obesity-related hypogonadism cases. More long-term, controlled studies with standardized fertility measures are needed to confirm their role in male reproductive health."

Journal • Review • Diabetes • Endocrine Disorders • Genetic Disorders • Infertility • Metabolic Disorders • Obesity • Sexual Disorders • Type 2 Diabetes Mellitus

Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus (clinicaltrials.gov) - P1/2 | N=50 | Enrolling by invitation | Sponsor: Ain Shams University

New P1/2 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Women's Health

Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024. (PubMed, J Drugs Dermatol) - "Cutaneous AEs are infrequent but vary by GLP-1 RA. Greater awareness may improve patient counseling as indications expand. &nbsp."

Adverse events • Journal • Alopecia • Cardiovascular • Dermatology • Diabetes • Hidradenitis Suppurativa • Immune Modulation • Immunology • Metabolic Disorders • Pruritus • Psoriasis • Type 2 Diabetes Mellitus • Urticaria

Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes. (PubMed, Diabetes Ther) - "Incretin-based therapy has shifted care from glucose-centric targets to cardiorenal risk reduction. GLP-1RA are guideline-endorsed for patients with T2DM and high CV/renal risk irrespective of HbA1c; dual agonists and oral small-molecule agents may broaden indications pending definitive outcome evidence."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus